Matrix-M adjuvant triggers inflammasome activation and enables antigen cross-presentation through induction of lysosomal membrane permeabilizationShow others and affiliations
2025 (English)In: npj Vaccines, E-ISSN 2059-0105, Vol. 10, no 1, article id 184Article in journal (Refereed) Published
Abstract [en]
Matrix-M® adjuvant, containing saponins, delivers a potent adjuvant effect and good safety profile. Given that Matrix-M is composed of Matrix-A and Matrix-C particles, comprising different saponin fractions, understanding their distinct roles can provide deeper insight into the mechanism of action of Matrix-M and guide future applications. Here, we demonstrate that the antigen and Matrix-M, Matrix-A, or Matrix-C colocalize in lysosomes following uptake by bone marrow–derived dendritic cells. Matrix-M, Matrix-A, and Matrix-C induce lysosomal membrane permeabilization (LMP), but Matrix-C shows the highest LMP potential. LMP is required for interleukin (IL)-1β and IL-18 secretion in vitro. In vivo, a robust adjuvant effect of Matrix-M, Matrix-A, and Matrix-C is observed, both in the presence and absence of the NLRP3 inflammasome. LMP induced by Matrix-M, as well as Matrix-A and Matrix-C, also enables antigen cross-presentation. Thus, Matrix-induced LMP explains the capability of Matrix-M–adjuvanted protein vaccines to induce CD8+ T-cell responses.
Place, publisher, year, edition, pages
Springer Nature, 2025. Vol. 10, no 1, article id 184
National Category
Immunology in the Medical Area
Identifiers
URN: urn:nbn:se:uu:diva-565595DOI: 10.1038/s41541-025-01243-5ISI: 001544699700002PubMedID: 40764493Scopus ID: 2-s2.0-105012604563OAI: oai:DiVA.org:uu-565595DiVA, id: diva2:1993941
Funder
Swedish Foundation for Strategic Research2025-09-012025-09-012025-09-01Bibliographically approved